Global drugmakers to conduct clinical trials in Ukraine

26 August 2016

The Ministry of Health of Ukraine has officially approved the conduct of clinical trials of drugs imported to the country – the initiative that has long been lobbied by global pharmaceutical majors, operating in the country.

It is planned that at the initial stage clinical trials of at least 100 drugs will be conducted in the territory of Ukraine, reports The Pharma Letter’s local correspondent.

To date, an interest for conducting clinical trials in the territory of Ukraine has been expressed by several global majors. For example, the US pharma giant Pfizer (NYSE: PFE) has announced its intention to test its new anti-cancer drug, as well as drugs for the treatment of pneumonia on the basis of hospitals in the Ukrainian cities of Cherkasy, Kyiv, Kherson and Vinnitsa.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK